CytarabineIdarubicinDaunorubicinLeukemia, Myeloid, AcuteRemission InductionAntineoplastic Combined Chemotherapy ProtocolsConsolidation ChemotherapyMitoxantroneAntimetabolites, AntineoplasticArabinonucleosidesDrug Administration ScheduleLeukemia, MyeloidEtoposideThioguanineTreatment OutcomeMethotrexateVincristineInduction ChemotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaInjections, SpinalMeningeal CarcinomatosisLeukemic InfiltrationAcute DiseaseCyclophosphamideCarmustineDisease-Free SurvivalCytidine MonophosphateAsparaginaseLymphoma, Non-HodgkinSurvival Analysis6-MercaptopurineDrug AgonismLeukemia, Myelomonocytic, AcuteArabinonucleotidesDeoxycytidine KinaseRecurrenceSurvival RateLeukemia, Myeloid, Accelerated PhaseSalvage TherapyCentral Nervous System NeoplasmsInfusions, IntravenousAmsacrineTransplantation, AutologousDoxorubicinVidarabineArabinofuranosylcytosine TriphosphateAntineoplastic AgentsCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTeniposideAnemia, Refractory, with Excess of BlastsDexamethasoneMyelodysplastic SyndromesMelphalanLeukemiaMeningitisDrug Resistance, NeoplasmPrednisonePodophyllotoxinCladribineLeukemia, Myeloid, Chronic-PhaseBlast CrisisAdenine NucleotidesPrognosisDioxolanesHarringtoninesHematopoietic Stem Cell TransplantationAclarubicinActuarial AnalysisPiperazinesPolyradiculopathyGranulocyte Colony-Stimulating FactorPyrimidinesBenzamidesCytogenetic AnalysisAdministration, OralDrug EvaluationDrug SynergismTime FactorsBurkitt LymphomaRadiation DosageMeningesLethal Dose 50Equilibrative Nucleoside Transporter 1Bone Marrow TransplantationDose-Response Relationship, DrugCore Binding FactorsLeukemia, Promyelocytic, AcuteLymphoma, Mantle-CellAntibodies, Monoclonal, Murine-DerivedLeukoencephalopathy, Progressive MultifocalAminoglycosidesLymphomaProspective StudiesFollow-Up StudiesInterferon-alphaPrednisoloneAzacitidinePapilledemaAnthracyclines